February 20, 2026
New Zealand has long maintained a conservative approach to consumer-facing promotion of prescription medicines. In 2025, that posture tightened further for medical cannabis access providers after Medsafe/Manatū Hauora (Ministry of Health) published updated Advertising Guidance: Medicinal Cannabis (July 2025) clarifying how existing law is being interpreted and enforced across websites, social media, brochures, and other patient-facing channels.
The net effect, as several industry groups and news reports have observed, is that many of the marketing practices that clinics adopted in recent years—especially product mentions, pricing talk, condition targeting, testimonials, and “THC/CBD” messaging—are now likely to be treated as prohibited advertising.
This article explains what the guidance is, why it’s being applied so broadly, what clinics and telehealth providers can still say online, and how to rebuild your digital funnel to stay compliant—without losing legitimate patient education.
Focus keyword: New Zealand medical cannabis advertising 2025 ban
Informational only. This is not legal advice. If you’re uncertain about a specific message, campaign, or landing page, obtain New Zealand legal/compliance advice.
New Zealand’s rules come from overlapping regimes:
The Ministry of Health’s Advertising medicinal cannabis products page links to the formal guidance and signals that regulators expect organizations to align to it in practice.
External references:
A key point for providers: the July 2025 document is guidance—but guidance is how enforcement reality is set. It provides examples of what Medsafe considers acceptable vs unacceptable, and it frames many routine clinic communications as “advertising” when they are accessible to the public.
Reporting (industry and international press) described the guidance as effectively prohibiting most public marketing by clinics.
Industry/news context:
Practical takeaway: If your content is public (indexable web pages, paid ads, organic social posts, downloadable brochures, public webinars), assume the regulator may treat it as advertising—even if your intention is “education.”
While every fact pattern matters, the 2025 guidance strongly signals risk for the following categories of content when presented publicly.
Public-facing references that could be read as promoting specific products, “THC” or “CBD” products, strengths, formats, or “what we stock” can be interpreted as advertising a medicine—especially where those products are prescription-only or unapproved medicines.
This includes:
Condition targeting can quickly become a therapeutic claim. Examples that are likely to be problematic include:
Even without explicit claims, implication matters. Words like relief, effective, fast-acting, safe alternative, or no side effects can be interpreted as therapeutic representations.
If testimonials imply therapeutic benefit, they can breach ASA rules and may also be viewed as advertising medicines.
High-risk examples:
Even “patient story” content can be treated as advertising if it’s used as promotional material.
Anything that looks like a retail promotion (specials, bundles, limited-time offers, referral bonuses) may increase the likelihood that regulators interpret your activity as advertising medicines rather than providing health services.
Be cautious about funnels that promise an outcome like:
Those messages can be construed as promotional and inconsistent with clinical decision-making.
The good news is that the guidance does not prohibit all communications. It draws a practical line around factual, non-promotional information, and recognizes that certain communications belong in professional or private clinical settings.
Below are the main categories that remain generally workable if you execute carefully.
You can usually publish factual information about your clinic as a health service, such as:
How to keep it non-promotional:
Education is still possible, but it must be structured to avoid becoming an ad.
Safer formats include:
What to avoid in educational content:
The guidance recognizes that information provided as part of a clinician–patient consultation is not the same as public advertising.
This supports a compliant model where:
The guidance describes limited circumstances where manufacturers/suppliers can communicate product education to HCPs (often on request and in controlled contexts). For clinics, the key lesson is to segregate professional materials:
Patient-facing materials can be permissible when they are clearly part of ongoing care:
Important nuance: If these materials are publicly downloadable and used as marketing collateral, they can be treated as advertising. Consider hosting them inside a patient portal or providing them after appointment booking.
Clinics that previously relied on SEO “condition pages” and product-driven CTAs should plan a rebuild that separates:
1) Public acquisition content (non-promotional, service-oriented)2) Private clinical content (patient-specific, consult-based)
Recommended page architecture:
Language swaps that help:
If you had a product list:
SEO can remain valuable, but shift from “product/condition conversion pages” to:
Keep calls-to-action factual:
Social can be used for:
Avoid:
If you use third parties:
Marketing compliance is now intertwined with privacy compliance—especially for clinics collecting health information through booking and intake tools.
Primary sources:
If you use Meta Pixel, Google Ads tags, retargeting, or conversion APIs, treat this as high sensitivity because clinic traffic can imply health status.
Checklist:
Health information is regulated under the Health Information Privacy Code 2020 and the Privacy Act 2020.
Checklist:
New Zealand’s anti-spam regime (UEMA) requires consent and functional unsubscribe mechanisms for commercial electronic messages.
Checklist:
Primary source:
In practice, enforcement is often complaint-driven. The most common triggers in this category tend to be:
Also consider that the ASA process can be fast-moving, public, and reputationally costly even before a regulator takes action.
If you’re a clinic operator, compliance lead, or agency supporting clinics, a structured sprint helps.
Regulatory guidance and advertising standards can shift quickly, especially as regulators respond to new marketing tactics.
If you need help tracking rule changes, translating guidance into website-safe copy, and operationalizing privacy and marketing controls, use https://cannabisregulations.ai/ to support your cannabis compliance program—so your clinic can focus on patient care while staying aligned with licensing and advertising regulations.
New Zealand has long maintained a conservative approach to consumer-facing promotion of prescription medicines. In 2025, that posture tightened further for medical cannabis access providers after Medsafe/Manatū Hauora (Ministry of Health) published updated Advertising Guidance: Medicinal Cannabis (July 2025) clarifying how existing law is being interpreted and enforced across websites, social media, brochures, and other patient-facing channels.
The net effect, as several industry groups and news reports have observed, is that many of the marketing practices that clinics adopted in recent years—especially product mentions, pricing talk, condition targeting, testimonials, and “THC/CBD” messaging—are now likely to be treated as prohibited advertising.
This article explains what the guidance is, why it’s being applied so broadly, what clinics and telehealth providers can still say online, and how to rebuild your digital funnel to stay compliant—without losing legitimate patient education.
Focus keyword: New Zealand medical cannabis advertising 2025 ban
Informational only. This is not legal advice. If you’re uncertain about a specific message, campaign, or landing page, obtain New Zealand legal/compliance advice.
New Zealand’s rules come from overlapping regimes:
The Ministry of Health’s Advertising medicinal cannabis products page links to the formal guidance and signals that regulators expect organizations to align to it in practice.
External references:
A key point for providers: the July 2025 document is guidance—but guidance is how enforcement reality is set. It provides examples of what Medsafe considers acceptable vs unacceptable, and it frames many routine clinic communications as “advertising” when they are accessible to the public.
Reporting (industry and international press) described the guidance as effectively prohibiting most public marketing by clinics.
Industry/news context:
Practical takeaway: If your content is public (indexable web pages, paid ads, organic social posts, downloadable brochures, public webinars), assume the regulator may treat it as advertising—even if your intention is “education.”
While every fact pattern matters, the 2025 guidance strongly signals risk for the following categories of content when presented publicly.
Public-facing references that could be read as promoting specific products, “THC” or “CBD” products, strengths, formats, or “what we stock” can be interpreted as advertising a medicine—especially where those products are prescription-only or unapproved medicines.
This includes:
Condition targeting can quickly become a therapeutic claim. Examples that are likely to be problematic include:
Even without explicit claims, implication matters. Words like relief, effective, fast-acting, safe alternative, or no side effects can be interpreted as therapeutic representations.
If testimonials imply therapeutic benefit, they can breach ASA rules and may also be viewed as advertising medicines.
High-risk examples:
Even “patient story” content can be treated as advertising if it’s used as promotional material.
Anything that looks like a retail promotion (specials, bundles, limited-time offers, referral bonuses) may increase the likelihood that regulators interpret your activity as advertising medicines rather than providing health services.
Be cautious about funnels that promise an outcome like:
Those messages can be construed as promotional and inconsistent with clinical decision-making.
The good news is that the guidance does not prohibit all communications. It draws a practical line around factual, non-promotional information, and recognizes that certain communications belong in professional or private clinical settings.
Below are the main categories that remain generally workable if you execute carefully.
You can usually publish factual information about your clinic as a health service, such as:
How to keep it non-promotional:
Education is still possible, but it must be structured to avoid becoming an ad.
Safer formats include:
What to avoid in educational content:
The guidance recognizes that information provided as part of a clinician–patient consultation is not the same as public advertising.
This supports a compliant model where:
The guidance describes limited circumstances where manufacturers/suppliers can communicate product education to HCPs (often on request and in controlled contexts). For clinics, the key lesson is to segregate professional materials:
Patient-facing materials can be permissible when they are clearly part of ongoing care:
Important nuance: If these materials are publicly downloadable and used as marketing collateral, they can be treated as advertising. Consider hosting them inside a patient portal or providing them after appointment booking.
Clinics that previously relied on SEO “condition pages” and product-driven CTAs should plan a rebuild that separates:
1) Public acquisition content (non-promotional, service-oriented)2) Private clinical content (patient-specific, consult-based)
Recommended page architecture:
Language swaps that help:
If you had a product list:
SEO can remain valuable, but shift from “product/condition conversion pages” to:
Keep calls-to-action factual:
Social can be used for:
Avoid:
If you use third parties:
Marketing compliance is now intertwined with privacy compliance—especially for clinics collecting health information through booking and intake tools.
Primary sources:
If you use Meta Pixel, Google Ads tags, retargeting, or conversion APIs, treat this as high sensitivity because clinic traffic can imply health status.
Checklist:
Health information is regulated under the Health Information Privacy Code 2020 and the Privacy Act 2020.
Checklist:
New Zealand’s anti-spam regime (UEMA) requires consent and functional unsubscribe mechanisms for commercial electronic messages.
Checklist:
Primary source:
In practice, enforcement is often complaint-driven. The most common triggers in this category tend to be:
Also consider that the ASA process can be fast-moving, public, and reputationally costly even before a regulator takes action.
If you’re a clinic operator, compliance lead, or agency supporting clinics, a structured sprint helps.
Regulatory guidance and advertising standards can shift quickly, especially as regulators respond to new marketing tactics.
If you need help tracking rule changes, translating guidance into website-safe copy, and operationalizing privacy and marketing controls, use https://cannabisregulations.ai/ to support your cannabis compliance program—so your clinic can focus on patient care while staying aligned with licensing and advertising regulations.
